Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CBN-1000 refers to a high-concentration cannabinol (CBN) product, typically formulated as an oil or tincture containing approximately 1,000 mg of cannabinol per bottle. Cannabinol is a minor cannabinoid found in Cannabis sativa and is structurally similar to THC but is non-intoxicating or only weakly psychoactive. It acts primarily as a weak agonist at the cannabinoid CB1 receptor and more potently at the CB2 receptor. Preclinical studies suggest that CBN may promote sleep by increasing both REM and non-REM sleep phases, with effects comparable to zolpidem in animal models. It also exhibits anti-inflammatory properties and may modulate pain via interaction with the endocannabinoid system. Recent research indicates potential for adjunctive use in estrogen receptor-positive breast cancer therapy when combined with exemestane, enhancing apoptosis and hormone modulation in preclinical models[6][10]. Commercially available formulations often include other cannabinoids such as CBD, CBC, or CBG for synergistic effects[7][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CBN-1000.